臨床検査63巻1号

2019年01月発行

今月の特集1 発症を予測する臨床検査—先制医療で5疾病に立ち向かう！

心疾患の先制医療

著者： 大塚文之¹ 安田聡¹

所属機関： ¹国立循環器病研究センター心臓血管内科

ページ範囲：P.18 - P.24

Point

●虚血性心疾患の多くは冠動脈硬化に起因し，動脈硬化性プラークの破綻によって血栓が形成され，急性冠症候群の発症に至る．

●急性冠症候群発症のハイリスク症例を同定するために，さまざまなバイオマーカーや画像診断技術が活用され，発症前の治療介入が試みられている．

●治療介入のなかでは，脂質低下薬として知られるスタチンによる心血管イベント抑制効果に関するエビデンスが豊富であり，ゲノム情報に基づくリスク層別化が治療の恩恵を受けやすい症例の抽出に役立つ可能性も示されている．

●個々のレベルでより正確にイベント発症リスクを予測し，適切なタイミングで効果的な治療介入を行うためには，さらなる研究成果の集積が必要である．

参考文献

1）厚生労働省：平成29年人口動態統計 第6表　性別にみた死因順位（第10位まで）別 死亡数・死亡率（人口10万対）・構成割合（https://www.mhlw.go.jp/toukei/saikin/hw/jinkou/kakutei17/dl/10_h6.pdf）（最終アクセス：2018年10月29日）

2）Cook NR, Paynter NP, Eaton CB, et al：Comparison of the Framingham and Reynolds Risk scores for global cardiovascular risk prediction in the multiethnic Women's Health Initiative. Circulation　125：1748-1756，2012

3）Ridker PM, Rifai N, Pfeffer M, et al：Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation　101：2149-2153，2000

4）Baldus S, Heeschen C, Meinertz T, et al：Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation　108：1440-1445，2003

5）Blankenberg S, Rupprecht HJ, Poirier O, et al：Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation　107：1579-1585，2003

6）Bayes-Genis A, Conover CA, Overgaard MT, et al：Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med　345：1022-1029，2001

7）Hayashida K, Kume N, Murase T, et al：Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels are elevated in acute coronary syndrome: a novel marker for early diagnosis. Circulation　112：812-818，2005

8）Libby P：Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond. J Am Coll Cardiol　70：2278-2289，2017

9）Heeschen C, Dimmeler S, Hamm CW, et al：Soluble CD40 ligand in acute coronary syndromes. N Engl J Med　348：1104-1111，2003

10）Soejima H, Ogawa H, Yasue H, et al：Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation　99：2908-2913，1999

11）Park KC, Gaze DC, Collinson PO, et al：Cardiac troponins: from myocardial infarction to chronic disease. Cardiovasc Res　113：1708-1718，2017

12）Wang Z, Klipfell E, Bennett BJ, et al：Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature　472：57-63，2011

13）Tang WH, Wang Z, Levison BS, et al：Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med　368：1575-1584，2013

14）Schunkert H, König IR, Kathiresan S, et al：Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet　43：333-338，2011

15）Mega JL, Stitziel NO, Smith JG, et al：Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet　385：2264-2271，2015

16）Natarajan P, Young R, Stitziel NO, et al：Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting. Circulation　135：2091-2101，2017

17）Stone GW, Maehara A, Lansky AJ, et al：A prospective natural-history study of coronary atherosclerosis. N Engl J Med　364：226-235，2011

18）Motoyama S, Sarai M, Harigaya H, et al：Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome. J Am Coll Cardiol　54：49-57，2009

19）Kawasaki T, Koga S, Koga N, et al：Characterization of hyperintense plaque with noncontrast T(1)-weighted cardiac magnetic resonance coronary plaque imaging: comparison with multislice computed tomography and intravascular ultrasound. JACC Cardiovasc Imaging　2：720-728，2009

20）Noguchi T, Kawasaki T, Tanaka A, et al：High-intensity signals in coronary plaques on noncontrast T1-weighted magnetic resonance imaging as a novel determinant of coronary events. J Am Coll Cardiol　63：989-999，2014

21）Asaumi Y, Noguchi T, Morita Y, et al：Non-contrast T1-weighted magnetic resonance imaging at 3.0 Tesla in a patient undergoing elective percutaneous coronary intervention - clinical and pathological significance of high-intensity plaque. Circ J　79：218-220，2015

22）Kanaya T, Noguchi T, Otsuka F, et al：Optical coherence tomography-verified morphological correlates of high-intensity coronary plaques on non-contrast T1-weighted magnetic resonance imaging in patients with stable coronary artery disease. Eur Heart J Cardiovasc Imaging, 2018, in press

23）SCOT-HEART Investigators, Newby DE, Adamson PD, et al：Coronary CT Angiography and 5-Year Risk of Myocardial Infarction. N Engl J Med　379：924-933，2018

24）Ridker PM, Cannon CP, Morrow D, et al：C-reactive protein levels and outcomes after statin therapy. N Engl J Med　352：20-28，2005

25）Ridker PM, Danielson E, Fonseca FA, et al：Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med　359：2195-2207，2008

26）Nissen SE, Nicholls SJ, Sipahi I, et al：Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA　295：1556-1565，2006

27）Schartl M, Bocksch W, Koschyk DH, et al：Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation　104：387-392，2001

28）Noguchi T, Tanaka A, Kawasaki T, et al：Effect of Intensive Statin Therapy on Coronary High-Intensity Plaques Detected by Noncontrast T1-Weighted Imaging: The AQUAMARINE Pilot Study. J Am Coll Cardiol　66：245-256，2015

29）Cannon CP, Blazing MA, Giugliano RP, et al：Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med　372：2387-2397，2015

30）Sabatine MS, Giugliano RP, Keech AC, et al：Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med　376：1713-1722，2017

31）Ridker PM, Everett BM, Thuren T, et al：Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med　377：1119-1131，2017